Postoperative Surveillance for Recurrent Malignant Disease

  • Geneviève Rondeau
  • Robert Michael Tuttle


The goals of initial therapy for thyroid cancer are to remove or destroy all evidence of disease while minimizing treatment-related side effects and unnecessary therapies. This initial management, if successful, should result in decreasing local or distant recurrence as well as disease-specific mortality. While certainly not a new concept, the last several years have seen a renewed interest in a risk-adapted approach to the management of thyroid cancer in which the extent and intensity of initial therapy is tailored according to individualized risk estimates of recurrence and mortality. Following thyroid surgery (either total thyroidectomy or hemi-thyroidectomy), patients continue a risk-adapted approach to ongoing thyroid cancer management based on standardized clinicopathologic factors that predict the risk of recurrence and/or mortality. In this approach, the risks and benefits of potential additional therapies are balanced against the specific risks of recurrence, mortality, and response to therapy for individual patients.


Thyroid Cancer Papillary Thyroid Carcinoma National Comprehensive Cancer Network National Comprehensive Cancer Network Differentiate Thyroid Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13(5):498–512PubMedGoogle Scholar
  2. 2.
    Tuttle RM (2008) Risk-adapted management of thyroid cancer. Endocr Pract 14(6):764–774PubMedGoogle Scholar
  3. 3.
    Hay ID (2006) Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94(8):692–700PubMedCrossRefGoogle Scholar
  4. 4.
    Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMedCrossRefGoogle Scholar
  5. 5.
    Tuttle RM (2010) National comprehensive cancer network, clinical practice guidelines in oncology, thyroid cancer. Cited 8 Apr 2010
  6. 6.
    Grebe SK, Hay ID (1996) Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5(1):43–63PubMedGoogle Scholar
  7. 7.
    Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86(4):1447–1463PubMedCrossRefGoogle Scholar
  8. 8.
    Sherman SI, Brierley JD, Sperling M et al (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83(5):1012–1021PubMedCrossRefGoogle Scholar
  9. 9.
    Lang BH, Lo CY, Chan WF et al (2007) Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245(3):366–378PubMedCrossRefGoogle Scholar
  10. 10.
    Tuttle RM, Lopez N, Leboeuf R et al (2010) Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20(3):257–263PubMedCrossRefGoogle Scholar
  11. 11.
    Baek SK, Jung KY, Kang SM et al (2010) Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20(2):147–152PubMedCrossRefGoogle Scholar
  12. 12.
    Orlov S, Orlov D, Shaytzag M et al (2009) Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31(6):782–788PubMedCrossRefGoogle Scholar
  13. 13.
    Bilimoria KY, Bentrem DJ, Ko CY et al (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246(3):375–381, discussion 381–384PubMedCrossRefGoogle Scholar
  14. 14.
    van Heerden JA, Hay ID, Goellner JR et al (1992) Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112(6):1130–1136, discussion 1136–1138PubMedGoogle Scholar
  15. 15.
    Liu J, Singh B, Tallini G et al (2006) Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107(6):1255–1264PubMedCrossRefGoogle Scholar
  16. 16.
    Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22(6):955–969PubMedCrossRefGoogle Scholar
  17. 17.
    Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8(1):83–95PubMedCrossRefGoogle Scholar
  18. 18.
    Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90(12):6373–6379PubMedCrossRefGoogle Scholar
  19. 19.
    Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399–5404PubMedCrossRefGoogle Scholar
  20. 20.
    Robbins RJ, Srivastava S, Shaha A et al (2004) Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 89(12):6010–6016PubMedCrossRefGoogle Scholar
  21. 21.
    Pacini F, Molinaro E, Castagna MG et al (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88(8):3668–3673PubMedCrossRefGoogle Scholar
  22. 22.
    Eustatia-Rutten CF, Smit JW, Romijn JA et al (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61(1):61–74CrossRefGoogle Scholar
  23. 23.
    Spencer CA (2004) Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 89(8):3702–3704PubMedCrossRefGoogle Scholar
  24. 24.
    Larson SM, Robbins R (2002) Positron emission tomography in thyroid cancer management. Semin Roentgenol 37(2):169–174PubMedCrossRefGoogle Scholar
  25. 25.
    Wang W, Larson SM, Tuttle RM et al (2001) Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11(12):1169–1175PubMedCrossRefGoogle Scholar
  26. 26.
    Robbins RJ, Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18 F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91(2):498–505PubMedCrossRefGoogle Scholar
  27. 27.
    Smallridge RC, Meek SE, Morgan MA et al (2007) Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92(1):82–87PubMedCrossRefGoogle Scholar
  28. 28.
    Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787–803PubMedCrossRefGoogle Scholar
  29. 29.
    Tuttle RM, Tala H, Shah J et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid 20(12):1341–1349PubMedCrossRefGoogle Scholar
  30. 30.
    McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34(7–8):554–564PubMedCrossRefGoogle Scholar
  31. 31.
    Biondi B, Filetti S, Schlumberger M (2005) Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1(1):32–40PubMedCrossRefGoogle Scholar
  32. 32.
    Biondi B, Cooper DS (2010) Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20(2):135–146PubMedCrossRefGoogle Scholar
  33. 33.
    Dean DS, Hay ID (2000) Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7(3):229–239PubMedGoogle Scholar
  34. 34.
    Byar DP, Green SB, Dor P et al (1979) A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15(8):1033–1041PubMedGoogle Scholar
  35. 35.
    Hay ID, Grant CS, Taylor WF et al (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102(6):1088–1095PubMedGoogle Scholar
  36. 36.
    Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6):947–953PubMedGoogle Scholar
  37. 37.
    Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114(6):1050–1057, discussion 1057–1058PubMedGoogle Scholar
  38. 38.
    Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97(5):418–428PubMedCrossRefGoogle Scholar
  39. 39.
    Shaha AR, Loree TR, Shah JP (1995) Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118(6):1131–1136, discussion 1136–1138PubMedCrossRefGoogle Scholar
  40. 40.
    Greene FL, Page DL, Fleming ID (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of MedicineEndocrinology Service, Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations